108 related articles for article (PubMed ID: 19890373)
1. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.
Vahdat AM; Reiners KS; Simhadri VL; Eichenauer DA; Böll B; Chalaris A; Simhadri VR; Wiegmann K; Krell HW; Rose-John S; Engert A; von Strandmann EP; Hansen HP
Leukemia; 2010 Jan; 24(1):51-7. PubMed ID: 19890373
[TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate.
Zhang Z; Oliver P; Lancaster JR; Schwarzenberger PO; Joshi MS; Cork J; Kolls JK
FASEB J; 2001 Feb; 15(2):303-5. PubMed ID: 11156944
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
6. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.
Böll B; Hansen H; Heuck F; Reiners K; Borchmann P; Rothe A; Engert A; Pogge von Strandmann E
Blood; 2005 Sep; 106(5):1839-42. PubMed ID: 15878978
[TBL] [Abstract][Full Text] [Related]
7. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme.
Hansen HP; Dietrich S; Kisseleva T; Mokros T; Mentlein R; Lange HH; Murphy G; Lemke H
J Immunol; 2000 Dec; 165(12):6703-9. PubMed ID: 11120787
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
9. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
10. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.
Hansen HP; Recke A; Reineke U; Von Tresckow B; Borchmann P; Von Strandmann EP; Lange H; Lemke H; Engert A
FASEB J; 2004 May; 18(7):893-5. PubMed ID: 15033921
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
13. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
[TBL] [Abstract][Full Text] [Related]
14. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
15. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Sorolla A; Yeramian A; Schoenenberger JA; Llombart-Cussac A; Marti RM; Matias-Guiu X; Dolcet X
Anticancer Drugs; 2008 Feb; 19(2):115-24. PubMed ID: 18176107
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium.
Yang X
Biomed Pharmacother; 2012 Dec; 66(8):607-11. PubMed ID: 23089480
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
Hansen HP; Matthey B; Barth S; Kisseleva T; Mokros T; Davies SJ; Beckett RP; Foelster-Holst R; Lange HH; Engert A; Lemke H
Int J Cancer; 2002 Mar; 98(2):210-5. PubMed ID: 11857410
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition activates the transport and the ectodomain shedding of TNF-alpha receptors in human endothelial cells.
Peiretti F; Canault M; Bernot D; Bonardo B; Deprez-Beauclair P; Juhan-Vague I; Nalbone G
J Cell Sci; 2005 Mar; 118(Pt 5):1061-70. PubMed ID: 15731011
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
20. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Martin SM; Churchill E; McKnight H; Mahaffey CM; Ma Y; O'Donnell RT; Tuscano JM
J Hematol Oncol; 2011 Dec; 4():49. PubMed ID: 22128838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
